News for Akari Therapeutics, Plc (AKTX)

Akari Therapeutics (AKTX) has successfully secured Patent No. 562,919 from Intellectual Property India, which encompasses the company's Thailanstatin Analogs. T

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through mul

Alliance Global Partners has revised its target price for Akari Therapeutics (AKTX), boosting it from $4 to $7 while maintaining a Buy rating. This adjustment r

Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical produ

Akari Therapeutics (AKTX) has unveiled a new "Meet the Team" video, highlighting Mark F. Kubik, who has recently taken on the role of Head of Business Developme

Akari Therapeutics (AKTX) to participate in the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. The event is scheduled for May

Live webcast on Thursday, May 29th at 2:20 PM ET BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc ( AKTX), an oncology biotechnol

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( CRBP), a clinical-stage company focused on oncology and obesity, today

Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with d

Akari Therapeutics (AKTX) is intensifying its focus on becoming a significant player in the antibody-drug conjugate (ADC) arena. The company's innovative ADC pl

Akari Therapeutics (AKTX) reports a reduced net loss of $3.7 million for Q1 2025, down from $5.6 million in Q1 2024. The company is focusing on developi

Akari Therapeutics (AKTX) appoints Mark F. Kubik as Head of Business Development - Oncology. Kubik brings over 25 years of experience in transformative

Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record acr

On April 16, 2025, Akari Therapeutics PLC (AKTX) released its 8-K filing detailing its financial results for the fiscal year ending December 31, 2024. Akari The

In 2024, Akari Therapeutics (AKTX) underwent a significant transformation, marked notably by the successful merger with Peak Bio Inc. This strategic move has en

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued pr

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning ...

**media[555729]**